Seres Therapeutics Corporate Overview March 2, 2021 Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing of clinical studies, the timing and ultimate results of the SER-109 safety data, the size of the ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - President and CEO Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Thome - Cowen & Company Mark Breidenbach - Oppenheimer Terence Flynn - Goldman Sachs Chris Howerton - Jefferies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or ...

Seres Therapeutics Eric Shaff, Chief Executive Officer 39th Annual J.P. Morgan Healthcare Conference January 14, 2021 Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing of clinical studies, the timin ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Carlo Tanzi - VP of IR & Corporate Communications Eric Shaff - President, CEO & Director Lisa von Moltke - EVP & Chief Medical Officer Matthew Henn - EVP & Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Thome - Cowen & Company John Newman - Canaccord Mark Breidenbach - Oppenheimer Chris Howerton ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisdiction of incorporation or organization) 200 Sidney Street - 4th Floor Cambridge, MA 021 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisd ...

April 2020 Seres Therapeutics Overview Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics or clinical trial data, the ability of our clinical trials to support approval, the timing of clinical studies, the sufficiency of cash to fund operations, and the potential ben ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Carlo Tanzi - VP of IR & Corporate Communications Eric Shaff - President, CEO & Director Lisa von Moltke - EVP & Chief Medical Officer Matthew Henn - EVP & Chief Scientific Officer Conference Call Participants Chris Shibutani - Cowen Melissa Hilton - Goldman Sachs Matthew Biegler - Oppenheimer Gbola Amusa - Chardan John Newman - Canaccord Vernon Bernardino - H.C. Wainwright Roger Song - Jeffer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisdiction of incorporation or organization) 200 Sidney Street - 4th Floor Cambridge, MA 02139 ...